Chimerix (NASDAQ:CMRX) Sets New 1-Year High – Here’s What Happened

Shares of Chimerix, Inc. (NASDAQ:CMRX) hit a new 52-week high during trading on Tuesday . The stock traded as high as $8.52 and last traded at $8.52, with a volume of 191012 shares trading hands. The stock had previously closed at $8.50.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Jefferies Financial Group restated a “hold” rating and issued a $8.50 price objective (down from $10.00) on shares of Chimerix in a research note on Wednesday, March 5th. HC Wainwright reissued a “neutral” rating and set a $8.55 target price (down previously from $11.00) on shares of Chimerix in a research report on Wednesday, March 5th. StockNews.com started coverage on Chimerix in a research note on Sunday. They issued a “hold” rating on the stock. Finally, Wedbush restated a “neutral” rating and set a $8.55 target price (up previously from $7.00) on shares of Chimerix in a research note on Wednesday, March 5th.

Chimerix Stock Performance

The firm has a market capitalization of $764.46 million, a price-to-earnings ratio of -9.04 and a beta of 0.32. The firm’s 50-day moving average price is $5.65 and its two-hundred day moving average price is $3.00.

Chimerix (NASDAQ:CMRX) last released its quarterly earnings data on Friday, March 21st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01. The company had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.31 million. As a group, equities research analysts anticipate that Chimerix, Inc. will post -0.99 EPS for the current year.

Insider Buying and Selling at Chimerix

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of Chimerix stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the transaction, the chief executive officer now owns 609,603 shares in the company, valued at approximately $2,755,405.56. The trade was a 1.19 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 20,760 shares of company stock worth $91,175 over the last ninety days. Corporate insiders own 13.10% of the company’s stock.

Institutional Trading of Chimerix

A number of hedge funds and other institutional investors have recently made changes to their positions in CMRX. Assenagon Asset Management S.A. grew its holdings in Chimerix by 154.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company’s stock worth $2,846,000 after acquiring an additional 496,823 shares during the last quarter. Rosalind Advisors Inc. bought a new stake in shares of Chimerix during the fourth quarter valued at approximately $10,614,000. Palumbo Wealth Management LLC acquired a new stake in shares of Chimerix in the fourth quarter valued at approximately $221,000. Valeo Financial Advisors LLC raised its position in Chimerix by 78.8% in the 4th quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company’s stock worth $509,000 after purchasing an additional 64,420 shares during the last quarter. Finally, Peapod Lane Capital LLC acquired a new position in shares of Chimerix during the fourth quarter valued at $2,626,000. 45.42% of the stock is currently owned by institutional investors and hedge funds.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.